Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development
- 1 December 2012
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 86 (23), 13005-13015
- https://doi.org/10.1128/jvi.01780-12
Abstract
Chikungunya virus (CHIKV) is an alphavirus which causes chronic and incapacitating arthralgia in humans. Although previous studies have shown that antibodies against the virus are produced during and after infection, the fine specificity of the antibody response against CHIKV is not known. Here, using plasma from patients at different times postinfection, we characterized the antibody response against various proteins of the virus. We have shown that the E2 and E3 glycoproteins and the capsid and nsP3 proteins are targets of the anti-CHIKV antibody response. Moreover, we have identified the different regions in these proteins which contain the linear epitopes recognized by the anti-CHIKV antibodies and determined their structural localization. Data also illustrated the effect of a single K252Q amino acid change at the E2 glycoprotein that was able to influence antibody binding and interaction between the antibodies and epitope because of the changes of epitope-antibody binding capacity. This study provides important knowledge that will not only aid in the understanding of the immune response to CHIKV infection but also provide new knowledge in the design of modern vaccine development. Furthermore, these pathogen-specific epitopes could be used for future seroepidemiological studies that will unravel the molecular mechanisms of human immunity and protection from CHIKV disease.This publication has 54 references indexed in Scilit:
- A Specific Domain of the Chikungunya Virus E2 Protein Regulates Particle Formation in Human Cells: Implications for Alphavirus Vaccine DesignJournal of Virology, 2012
- Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical ProtectionThe Journal of Infectious Diseases, 2012
- Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoproteinEMBO Molecular Medicine, 2012
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- I-TASSER: a unified platform for automated protein structure and function predictionNature Protocols, 2010
- A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infectionNature Medicine, 2010
- Prophylaxis and Therapy for Chikungunya Virus InfectionThe Journal of Infectious Diseases, 2009
- Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirusJournal of General Virology, 2007
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953Transactions of the Royal Society of Tropical Medicine and Hygiene, 1955